An investigator-sponsored open label pilot study at Massachusetts General Hospital (MGH) in Boston demonstrated the feasibility of long-term administration of RNS60 by once weekly intravenous infusion and once daily inhalation (nebulization) on the non-infusion days to people with ALS. Treatment with RNS60 was administered over the course of 23 weeks, followed by an optional 24-week extension period. Tolerability and compliance were high, there were no treatment-related serious adverse events, and no participant withdrew from the trial because of side effects.

Link to the article: A pilot trial of RNS60 in amyotrophic lateral sclerosis – Paganoni – 2019 – Muscle & Nerve – Wiley Online Library